Skip to main navigation Skip to search Skip to main content

Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?

  • Sara De Carolis
  • , Angela Botta
  • , Silvia Salvi
  • , E. Di Pasquo
  • , G. Del Sordo
  • , C. Garufi
  • , Antonio Lanzone
  • , M. P. De Carolis

Research output: Contribution to journalArticle

Abstract

The best therapy regimen for refractory obstetrical antiphospholipid syndrome remains to be determined. Additional treatments with steroids, plasma exchanges and immunoglobulins failed to show any beneficial effect. We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment. Furthermore, we highlighted that HCQ was able to dramatically reduce the antiphospholipid antibodies levels.
Original languageEnglish
Pages (from-to)760-762
Number of pages3
JournalAutoimmunity Reviews
Volume14
DOIs
Publication statusPublished - 2015

Keywords

  • Antibodies, Antiphospholipid
  • Antiphospholipid Syndrome
  • Hydroxychloroquine
  • Pregnancy
  • Pregnancy Complications
  • Pregnancy Outcome

Fingerprint

Dive into the research topics of 'Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?'. Together they form a unique fingerprint.

Cite this